Osteonecrosis Maxilar asociada a bifosfonatos en Cali, Colombia
Barra lateral del artículo
Contenido principal del artículo
Antecedentes: Después de más de 15 años del primer reporte de osteonecrosis asociada a bifosfonato (BP), siguen reportándose casos relacionados con este y con otros medicamentos, dándose el aumento en el número de prescripciones.
Objetivo: Caracterizar pacientes con osteonecrosis de maxilar asociada a bifosfonatos (BRONJ), atendidos en la ciudad de Cali, Colombia.
Materiales y Métodos: Se realizó una encuesta estructurada a 32 cirujanos maxilofaciales de la ciudad de Cali, Colombia, donde se preguntó sobre diferentes tópicos relacionados con pacientes afectados y desarrollo de la patología como edad y genero de los pacientes, tipo de medicamento, tiempo de administración, hueso expuesto, etc.
Resultados: Treinta y dos cirujanos maxilofaciales respondieron la encuesta con un total de 8 casos. Se encontró 6 casos correspondieron a mujeres y 2 a hombres, la edad fue superior a 44 años; 4 de los tratamientos con bifosfonatos fueron de prescripción oral y 4 intravenoso. La mayor parte de los casos de osteonecrósis se presentaron en mandíbula (88%) y 6 casos (75%) presentaron exposición de hueso.
Conclusiones: La osteonecrosis asociada a bifosfonatos es una situación que todavía se presenta, es necesario que la comunidad de pacientes y el personal de salud conozcan más sobre esta situación.
Shibahara T, Morikawa T, Yago K, Kishimoto H, Imai Y, Kurita K. National Survey on Bisphosphonate-Related Osteonecrosis of the Jaws in Japan. J Oral Maxillofac Surg [Internet]. 2018;76(10):2105–12. Available from: https://doi.org/10.1016/j.joms.2018.04.009
Gómez, J ; Sanders, K; Laguna, F; Montaño C. Osteonecrosis asociada a bifosfonatos: su influencia en la práctica odontológica. Rev ADM. 2009;LXV(4):36:44.
Guo Z, Cui W, Que L, Li C, Tang X, Liu J. Pharmacogenetics of medication-related osteonecrosis of the jaw: a systematic review and meta-analysis. Int J Oral Maxillofac Surg. 2019;49(3):298–309.
George EL, Lin YL, Saunders MM. Bisphosphonate-related osteonecrosis of the jaw: a mechanobiology perspective. Bone Reports [Internet]. 2018;8:104–9. Available from: https://doi.org/10.1016/j.bonr.2018.03.003
Cariolatto F, Carelli J, Taís M, Pietrobon R, Rodrigues C, Bonilauri A. Recommendations for the Prevention of Bisphosphonate-Related Osteonecrosis of the Jaw: A Systematic Review. J Evid Based Dent Pract [Internet]. 2018;18(2):142–52. Available from: https://doi.org/10.1016/j.jebdp.2017.11.002
Balkhi B, Seoane-Vazquez E, Rodriguez-Monguio R. Changes in the utilization of osteoporosis drugs after the 2010 FDA bisphosphonate drug safety communication. Saudi Pharm J [Internet]. 2018;26(2):238–43. Available from: https://doi.org/10.1016/j.jsps.2017.12.005
Wotton CJ, Green J, Brown A, Armstrong MEG, Floud S, Beral V, et al. Use of oral bisphosphonates and risk of hospital admission with osteonecrosis of the jaw: Large prospective cohort study in UK women. Bone [Internet]. 2019;124(April):69–74. Available from: https://doi.org/10.1016/j.bone.2019.04.003
Wang Q, Liu J, Qi S, Liao X, Liu D, Pan J. Clinical analysis of medication related osteonecrosis of the jaws: A growing severe complication in China. J Dent Sci [Internet]. 2018;13(3):190–7. Available from: https://doi.org/10.1016/j.jds.2017.12.003
Duarte NT, Rech B de O, Martins IG, Franco JB, Ortega KL. Can children be affected by bisphosphonate-related osteonecrosis of the jaw? A systematic review. Int J Oral Maxillofac Surg. 2019;49(2):83–191.
Ristow O, Rückschloß T, Müller M, Berger M, Kargus S, Pautke C, et al. Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study. J Cranio-Maxillofacial Surg [Internet]. 2019;47(3):491–9. Available from: https://doi.org/10.1016/j.jcms.2018.12.014
Matsuda S, Yoshimura H, Sano K. Risk factors and treatments for medication-related osteonecrosis of the jaw: A 10-year single-institution experience. J Oral Maxillofac Surgery, Med Pathol [Internet]. 2018;30(1):10–6. Available from: https://doi.org/10.1016/j.ajoms.2017.08.004
Kuroshima S, Sasaki M, Sawase T. Medication-related osteonecrosis of the jaw: A literature review. J Oral Biosci [Internet]. 2019;61(2):99–104. Available from: https://doi.org/10.1016/j.job.2019.03.005
Hallmer F, Andersson G, Götrick B, Warfvinge G, Anderud J, Bjørnland T. Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw—a 4-year prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;126(6):477–85.
Sammut S, Malden N, Lopes V, Ralston S. Epidemiological study of alendronate-related osteonecrosis of the jaw in the southeast of Scotland. Br J Oral Maxillofac Surg [Internet]. 2016;54(5):501–5. Available from: http://dx.doi.org/10.1016/j.bjoms.2015.10.036
Yuan A, Munz A, Reinert S, Hoefert S. Gingival fibroblasts and medication-related osteonecrosis of the jaw: Results by real-time and wound healing in vitro assays. J Cranio-Maxillofacial Surg [Internet]. 2019;47(9):1464–74. Available from: https://doi.org/10.1016/j.jcms.2019.06.004
Lemound J, Muecke T, Zeller AN, Lichtenstein J, Eckardt A, Gellrich NC. Nasolabial Flap Improves Healing in Medication-Related Osteonecrosis of the Jaw. J Oral Maxillofac Surg. 2018;76(4):877–85.
Ribeiro GH, Chrun ES, Dutra KL, Daniel FI, Grando LJ. Osteonecrosis of the jaws: a review and update in etiology and treatment. Braz J Otorhinolaryngol [Internet]. 2018;84(1):102–8. Available from: http://dx.doi.org/10.1016/j.bjorl.2017.05.008
Cortés-Motta MC, Fernández-Grisales R. Osteonecrosis de los maxilares: fisiopatología, diagnóstico y tratamiento. CES Odontol. 2016;29(2):65–77.
Pichardo SEC, Kuijpers SCC, van Merkesteyn JPR. Bisphosphonate-related osteonecrosis of the jaws: Cohort study of surgical treatment results in seventy-four stage II/III patients. J Cranio-Maxillofacial Surg [Internet]. 2016;44(9):1216–20. Available from: http://dx.doi.org/10.1016/j.jcms.2016.06.016
Pichardo S, Broek F, Van Merkesteyn JP. Treatment of pathologic fractures of the mandible in stage III medication-related osteonecrosis of the jaw—an observational study. J Cranio-Maxillofacial Surg [Internet]. 2018;46(8):1241–1246. Available from: https://doi.org/10.1016/j.jcms.2018.05.025
Topaloglu G, Koseoglu OT, Karaca C, Kosemehmetoglu K. The effect of chronic dental inflammation on development of Stage 0 medication-related osteonecrosis of the jaw. J Cranio-Maxillofacial Surg [Internet]. 2017;45(8):1158–1164. Available from: http://dx.doi.org/10.1016/j.jcms.2017.05.003
Song M, Alshaikh A, Kim T, Kim S, Dang M, Mehrazarin S, et al. Preexisting Periapical Inflammatory Condition Exacerbates Tooth Extraction–induced Bisphosphonate-related Osteonecrosis of the Jaw Lesions in Mice. J Endod [Internet]. 2016;42(11):1641–1646. Available from: http://dx.doi.org/10.1016/j.joen.2016.07.020
Kuroshima S, Sasaki M, Nakajima K, Tamaki S, Hayano H, Sawase T. Prevalence of bisphosphonate-related osteonecrosis of the jaw-like lesions is increased in a chemotherapeutic dose-dependent manner in mice. Bone [Internet]. 2018;112:177–86. Available from: https://doi.org/10.1016/j.bone.2018.05.001
Zandi M, Dehghan A, Janbaz P, Malekzadeh H, Amini P. The starting point for bisphosphonate-related osteonecrosis of the jaw: Alveolar bone or oral mucosa? A randomized, controlled experimental study. J Cranio-Maxillofacial Surg [Internet]. 2017;45(1):157–161. Available from: http://dx.doi.org/10.1016/j.jcms.2016.10.015
Signi C. Bisphosphonate suspension and osteonecrosis of the jaw. Dent Abstr. 2018;63(4):269–270.
Kawakita A, Yanamoto S, Morishita K, Naruse T, Hayashida S, Soutome S, et al. Discontinuing oral bisphosphonate therapy during dental extraction does not prevent osteonecrosis of the jaw: A multicenter retrospective study of 341 patients with propensity score matching analysis. J Oral Maxillofac Surgery, Med Pathol [Internet]. 2017;2029(6):522–526. Available from: https://doi.org/10.1016/j.ajoms.2017.07.008
Maeda CY, Da Mata PS, Cavalcanti DR, Martini Rodrigues SC, Marcucci M. Knowledge and Attitudes of Brazilian Dental Students About Bisphosphonate-Related Osteonecrosis of the Jaw. Oral Surg Oral Med Oral Pathol Oral Radiol [Internet]. 2018;23(12):342(12):3421–3426. Available from: https://doi.org/10.1016/j.oooo.2018.02.630
Franchi S, Brucoli M, Boffano P, Dosio C, Benech A. Medical students’ knowledge of Medication Related Osteonecrosis of the Jaw. J Stomatol Oral Maxillofac Surg [Internet]. 2019. (19)30250-2 Available from: https://doi.org/10.1016/j.jormas.2019.10.005
Escobedo M, García-Consuegra L, Junquera S, Olay S, Ascani G, Junquera L. Medication-related osteonecrosis of the jaw: A survey of knowledge, attitudes, and practices among dentists in the principality of Asturias (Spain). J Stomatol Oral Maxillofac Surg. 2018;119(5):395–400.
García-Martínez L, Martín-Payo R, Pelaz-García A, Sierra-Vega M, Junquera-Gutiérrez LM. Intervention to improve awareness of the risk factors for osteonecrosis of the jaw in patients under treatment with bisphosponates. Randomised clinical trial. Enfermería Clínica [Internet]. 2017;27(6):352–360. Available from: http://dx.doi.org/10.1016/j.enfcle.2017.04.008
Escobedo MF, Cobo JL, Junquera S, Milla J, Olay S, Junquera LM. Medication-related osteonecrosis of the jaw. Implant presence-triggered osteonecrosis: Case series and literature review. J Stomatol Oral Maxillofac Surg [Internet]. 2019;121(1):40–48. Available from: https://doi.org/10.1016/j.jormas.2019.04.012
Kishimoto H, Noguchi K, Takaoka K. Novel insight into the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Jpn Dent Sci Rev [Internet]. 2019;55(1):95–102. Available from: https://doi.org/10.1016/j.jdsr.2018.09.002
Tandon S, Lamba AK, Faraz F, Aggarwal K, Chowdhri K. A case report of bisphosphonate related osteonecrosis of the jaw treated by photodynamic therapy. Photodiagnosis Photodyn Ther [Internet]. 2019;26(April):313–315. Available from: https://doi.org/10.1016/j.pdpdt.2019.04.017
Nisi M, Karapetsa D, Gennai S, Ramaglia L, Graziani F, Gabriele M. Conservative surgical treatment of medication related osteonecrosis of the jaw (MRONJ) lesions in patients affected by osteoporosis exposed to oral bisphosphonates: 24 months follow-up. J Cranio-Maxillofacial Surg [Internet]. 2018;46(7):1153–1158. Available from: https://doi.org/10.1016/j.jcms.2018.05.003
Kim HY, Lee SJ, Kim SM, Myoung H, Hwang SJ, Choi JY, et al. Extensive Surgical Procedures Result in Better Treatment Outcomes for Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Osteoporosis. J Oral Maxillofac Surg [Internet]. 2017;75(7):1404–1413. Available from: http://dx.doi.org/10.1016/j.joms.2016.12.014
Nicolatou-Galitis O, Schiødt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol [Internet]. 2019;127(2):117–135. Available from: https://doi.org/10.1016/j.oooo.2018.09.008
Descargas
Los autores/as conservan los derechos de autor y ceden a la revista el derecho de la primera publicación, con el trabajo registrado con la licencia de atribución de Creative Commons, que permite a terceros utilizar lo publicado siempre que mencionen la autoría del trabajo y a la primera publicación en esta revista.